MannKind Corporation (MNKD) shares tumbled 6.75% in pre-market trading on Monday following the company's announcement to discontinue its ICON-1 Phase 3 clinical trial. The trial was testing nebulized clofazimine for NTM lung disease, a key pipeline candidate for the biopharmaceutical company.

The decision to halt the trial came after an independent Data Safety Monitoring Board (DSMB) agreed to discontinue the study due to futility. This means that the trial was unlikely to meet its primary efficacy endpoints, dealing a significant blow to MannKind's drug development efforts in this area.

Despite this setback, the company stated that the development of MNKD-102 remains under consideration. However, the discontinuation of the ICON-1 trial represents a major setback for MannKind's pipeline, which likely explains the sharp decline in its stock price. Investors are reassessing the company's growth prospects in light of this development.